| Adjuvant treatment | 191 |
| Africa | 28 |
| And clinical outcomes | 115 |
| Artificial intelligence | 261, 262 |
| Automated breast ultrasound | 311 |
| Axillary lymph node dissection | 229, 318 |
| Axillary lymph node metastasis | 115 |
| Axillary surgery | 318 |
| Axillary treatment | 229 |
| BCS | 99 |
| Benign breast lesions | 166 |
| Bioinformatics | 45 |
| Biomarkers | 45 |
| Biopsy | 1, 76 |
| Body mass index | 210 |
| BRCA1 | 235 |
| BRCA1/2 | 55 |
| BRCA2 | 235 |
| Breast | 1, 253 |
| Breast cancer | 28, 34, 45, 55, 70, 76, 85, 99, 121, 128, 159, 191, 201, 229, 235, 274, 297, 325, 331 |
| Breast cancer management | 186 |
| Breast cancer risk | 222, 267 |
| Breast cancer screenings | 279 |
| Breast conserving surgery | 287, 331 |
| Breast hematoma | 257 |
| Breast imaging | 99, 262, 304 |
| Breast magnetic resonance imaging | 140 |
| Breast neoplasm | 177 |
| Breast pain | 210 |
| Breast reconstruction | 172 |
| Breast self-examination | 215 |
| Breast-conserving surgery | 318 |
| Breast | 335 |
| Cancer | 1, 92 |
| Capecitabine | 128 |
| CDH1/PALB2 | 55 |
| Chemoprevention | 267 |
| Chemoresistance | 45 |
| Chemotherapy | 186 |
| Clinicopathologic characteristics | 115 |
| Complex decongestive treatment | 34 |
| Complex sclerosing lesion | 166 |
| Conformity | 92 |
| Conserving therapy | 121 |
| Cosmetic outcome | 287 |
| CYSLTR1 | 148 |
| Diagnostic techniques | 262 |
| Ductal carcinoma in situ | 140, 253 |
| Early breast cancer | 229 |
| Early detection of cancer | 215 |
| Early diagnosis | 222 |
| Elderly women | 201 |
| F-18 FDG | 159 |
| Fear | 70 |
| Genetic testing | 55 |
| Genomic profiling | 235 |
| Goldilocks mastectomy | 172 |
| Gynaecomastia | 304 |
| Handheld ultrasound | 311 |
| HER2/neu receptor | 128 |
| Homogeneity | 92 |
| Immigrant | 222 |
| International survey | 201 |
| Interventional | 262 |
| Ki-67 | 274 |
| Kinesio-taping | 34 |
| Lapatinib | 128 |
| Leukotriene | 148 |
| Liposarcoma | 335 |
| Local relapse | 191 |
| Locoregional treatment | 110 |
| Low level laser therapy | 34 |
| Lymph node | 253 |
| Lymphedema | 34 |
| Magnetic resonance imaging | 1, 85, 335 |
| Male breast | 304 |
| Mammography | 70, 76, 85, 140, 279 |
| Manual lymphatic drainage | 34 |
| Mastalgia | 210 |
| Mastectomy | 92, 121, 134 |
| Mechanical support | 210 |
| Mediators of inflammation | 148 |
| Metastasis | 128, 191, 274 |
| Metastatic breast carcinoma | 110 |
| Molecular subtypes | 186 |
| Navigation | 28 |
| Neoadjuvant chemotherapy | 45, 99, 159 |
| Nipple areola complex | 172 |
| Nursing | 215 |
| Oligometastatic disease | 110 |
| Oncoplastic breast surgery | 261 |
| Oncotype DX recurrence score | 325 |
| Operational cost | 311 |
| Oral anticoagulant | 257 |
| Pandemic | 177 |
| Patient | 177 |
| Patient care | 28 |
| Phyllodes tumor | 191 |
| Pleomorphic | 335 |
| Population study | 235 |
| PREDICT tool | 325 |
| Preventive behaviors | 279 |
| Psycho-oncology | 297 |
| Pure tubular breast carcinoma | 115 |
| Pyoderma gangrenosum | 331 |
| Quality of life | 121, 210 |
| Quality-of-life | 287 |
| Radial scar | 76, 166 |
| Radiologist | 311 |
| Radiology | 262 |
| Radiotherapy | 92, 287 |
| Reassurance | 210 |
| Reconstruction | 121 |
| Recurrence | 85, 191 |
| Regressive changes | 140 |
| Resilience | 297 |
| Sclerosant | 134 |
| Screening | 201, 262 |
| SCUBE2 | 45 |
| Senologic international society | 201 |
| Sentinel lymph node biopsy | 186, 229, 318 |
| Seroma | 134, 318 |
| Silver rod localization | 99 |
| Spiculated lesion | 166 |
| Spiritual well-being | 297 |
| Src inhibitors | 267 |
| Supportive care | 297 |
| Surgery | 186 |
| Surgical planning | 261 |
| Survival | 110 |
| SUVmax | 159 |
| Systemic therapy | 110 |
| TAILORx risk categorization | 325 |
| Theranostics | 262 |
| Therapeutic | 177 |
| Time savings | 311 |
| TP53/PTEN | 55 |
| Treatment | 201, 257 |
| Triple negative breast cancer | 274 |
| Triple-negative breast cancer | 148 |
| Ultrasound | 76, 85, 140 |
| Upgrade | 76 |
| Women | 215 |
| Worry | 279 |